CMS Open Payments · Program Year 2024
Glaukos Corporation
Glaukos Corporation reported $10,818,213.23 across General Payments, Research, and Ownership to 11,456 physicians and teaching hospitals across 14,015 transactions.
- $10.8M
- All-tracks total
- 14,015
- Transactions
- 11,456
- Recipients
- −$206.5K
- General Payments vs PY2023
Glaukos Corporation reported $10,818,213.23 across all CMS Open Payments tracks (General + Research + Ownership) to 11,456 physicians and teaching hospitals in Program Year 2024 - ranking #159 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $3,563,133.82, averaging $944.33 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer glaukos-corporation Glaukos Corporation
$10.8M · #159/1,925 · 0.1% industry · PY2024
- TOT $10.8M
- RANK #159
- SHARE 0.1%
- TXN 14,015
- RCP 11,456
- CAT 8
- GEN $3.6M
- ΔGEN −$206.5K
- TOP1 5.0%
- PY 2024
Volume peers
Nearest volume peer: Mesh Suture Inc ($10.8M)
Glaukos Corporation sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Glaukos Corporation's CMS-reported General Payments decreased by $206.5K (−5.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: GLAUKOS CORPORATIONPY2023: GLAUKOS CORPORATIONPY2024: Glaukos Corporation. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $3,769,593.29
- PY2024
- $3,563,133.82
What the Data Shows for Glaukos Corporation
Rank #159 of 1,925 companies in CMS Open Payments for 2024 belongs to Glaukos Corporation, which reported $10,818,213.23 across 14,015 transactions to 11,456 recipients - a comparatively small 0.1% slice of all industry payments reported nationwide for the year. Averages work out to $771.90 per transaction and $944.33 per recipient.
735 transactions worth $2.1M make "Consulting Fee" the top general-payment category in the 8-category breakdown below, 59.4% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Consulting Fee" leads Glaukos Corporation's 8-category general-payment breakdown at $2.1M, 59.4% of the reported total.
Glaukos Corporation reports 8 general-payment categories - the top three are Consulting Fee (59.4%), Food and Beverage (21.1%), and Long-Term Medical Supply or Device Loan (7.5%). The remaining 5 categories make up 12.1% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
Category breadth matters here: Glaukos Corporation files across 8 named CMS general-payment types in Program Year 2024, versus manufacturers that report a single dominant category. The chart and table below enumerate every type with an amount above zero for this company.
How Glaukos Corporation divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $2.1M | 735 | 59.4% |
| Food and Beverage | $751.0K | 10,375 | 21.1% |
| Long-Term Medical Supply or Device Loan | $266.0K | 38 | 7.5% |
| Travel and Lodging | $176.3K | 206 | 4.9% |
| Compensation for Services Other Than Consulting | $86.6K | 83 | 2.4% |
| Royalty or License | $84.2K | 2 | 2.4% |
| Grant | $47.4K | 5 | 1.3% |
| Space Rental or Facility Fees | $36.2K | 12 | 1.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $667,577.84 (18.7%) of $3,563,133.82 in this company's General Payments records across 5,803 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Glaukos Corporation
The five named recipients with the highest reported General Payments from this company
- 1
Mark Gallardo
$176,595.15 across 45 reported transactions
- 2
Oluwatosin Smith
$157,895.70 across 14 reported transactions
- 3
Savak Teymoorian
$128,189.35 across 58 reported transactions
- 4
Stephanie Woo
$112,850.02 across 7 reported transactions
- 5
Iqbal Ahmed
$92,047.62 across 14 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Glaukos Corporation's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Glaukos Corporation.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Glaukos Corporation.
Showing 6 of 1,924 companies with CMS-reported payment data.
Alafair Biosciences, Inc.
TG Therapeutics, Inc.
Ortho-Clinical Diagnostics, Inc.
Sanofi-Aventis U.s. LLC
Lexicon Pharmaceuticals, Inc.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.